Downward pressure and price drops in Jaguar Health shares are typically driven by recurring challenges faced by micro-cap biotech firms, including heavy dilution from equity offerings, capital-raising requirements to fund ongoing clinical trials, and delays in commercial revenue scaling. Additionally, broader market sell-offs affecting speculative healthcare equities and periodic setbacks in regulatory approval timelines heavily impact investor sentiment and short-term valuations.